retatrutide clinical trials safety A new clinical trial from Eli Lilly and Company suggests its experimental 🚨Breaking: Retatrutide's first Phase 3

Journal of Sexual Medicine / PMC Clinical review: how GLP-1 obesity medications may decrease sexual desire PMC (NIH) Anorgasmia following initiation of a GLP-1 agonist PLOS One / PMC Weight loss, testosterone, SHBG, and erectile function in overweight and obese men Andrologia (meta-analysis) Effect of weight loss on erectile function in men with overweight or obesity PubMed Sexual Function, Obesity, and Weight Loss in Men and Women PMC (NIH) / Healthcare Hormonal profile, weight, and sexual function in women with PCOS Indiana University, Kinsey Institute Survey on GLP-1s, sex, and dating

Semaglutide is used to support appetite control, blood sugar regulation, and weight management under medical supervision

Shimizu, I., Hirota, M., Ohboshi, C

Conclusions First, it is too early to conclude that advancing type 2 diabetes is characterised by a progressive loss of the potential to secrete GLP-1 as part of the process of disease progression

Clinical Trials Show Results Clinical trials have shown patients on these amazing drugs lost an average ~15% of their body weight or ~35 lbs, but with longer-term yields showed results in a weight loss of 30%